InpharmD™





Add Drug Information Pharmacists

Without Adding FTEs

So you can practice at top of license.

Get Started Free

Trusted by 20,000+ clinical pharmacists.

Play Circle

Learn about InpharmD™ in under 90 seconds

What is InpharmD™?


Literature searching is tedious. InpharmD™ is here to help.

Clinical pharmacists can ask any question, anytime, from anywhere, and we’ll perform a custom literature search.

(And a 32% chance it’s already been asked.)


More than 30 of the world's best health systems hire an InpharmD™ virtual DI pharmacist, yielding:


165,040

Clinical Pharmacist Hours Saved

4x +

ROI

100%

Customer Satisfaction Rate

This is how InpharmD™ transforms LITERATURE.

What's Being Asked...

What are the antibiotic recommendations regarding IR guided Suprapubic catheter placements and exchanges? Are there r...
Provide a summary of aflibtercept biosimilar switching studies, including any available from Europe.
What are the preferred irrigation solutions for spinal surgery? Do they differ for clean and contaminated procedures?...
Should edentulous patients with dentures who are starting Zometa for metastatic osseous disease obtain a dental clear...
What alternatives can be used for oral contrast for CT since Omnipaque oral is not available. What is data on using ...

What would you like to ask InpharmD™?

InpharmD's Answer GPT's Answer

Author:Muna Said, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Direct evidence for prophylaxis during IR-guided suprapubic catheter placement and exchange is limited, and guidelines differ. Guidance from the Society of Interventional Radiology, primarily addressing nephrostomy and ureteral procedures, generally recommends prophylaxis for initial placement but not routine exchange in uninfected, unobstructed, immunocompetent patients; options include cefazolin, ceftriaxone, ampicillin–sulbactam, or ampicillin plus gentamicin. Factors warranting prophylaxi...

Guidelines published by the Society of Interventional Radiology in 2010 primarily address percutaneous nephrostomy placement, exchange, and ureteral stents, although recommendations may potentially be extrapolated to suprapubic catheter placement or exchange. For these urinary interventions, the authors generally recommend antibiotic prophylaxis for initial placement, whereas routine exchange does not warrant prophylaxis in uninfected, unobstructed, immunocompetent patients. Factors predisposing to infection include advanced age, diabetes, bladder dysfunction, an indwelling catheter, previous urinary tract manipulation, ureterointestinal anastomosis, bacteriuria, and stones; patients with these risk factors should receive an appropriate antibiotic before intervention. The guideline identifies no preferred regimen but lists intravenous cefazolin 1 g, ceftriaxone 1 g, ampicillin/sulbactam 1.5–3 g, or ampicillin 2 g plus gentamicin 1.5 mg/kg as common options. When clinical infection i...

READ MORE→

A search of the published medical literature revealed 4 studies investigating the researchable question:

What are the recommendations for antibiotic prophylaxis during interventional radiology (IR) guided suprapubic catheter placement and exchange, and which patient or procedural risk factors determine whether prophylaxis is indicated?

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Venkatesan AM, Kundu S, Sacks D, Wallace MJ, Wojak JC, Rose SC, Clark TW, d'Othee BJ, Itkin M, Jones RS, Miller DL, Owens CA, Rajan DK, Stokes LS, Swan TL, Towbin RB, Cardella JF; Society of Interventional Radiology Standards of Practice Committee. Practice guidelines for adult antibiotic prophylaxis during vascular and interventional radiology procedures. Written by the Standards of Practice Committee for the Society of Interventional Radiology and Endorsed by the Cardiovascular Interventional Radiological Society of Europe and Canadian Interventional Radiology Association [corrected]. J Vasc Interv Radiol. 2010 Nov;21(11):1611-30; quiz 1631. doi: 10.1016/j.jvir.2010.07.018
[2] Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, Eckert LO, Geerlings SE, Köves B, Hooton TM, Juthani-Mehta M, Knight SL, Saint S, Schaeffer AJ, Trautner B, Wullt B, Siemieniuk R. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019 May 2;68(10):1611-1615. doi: 10.1093/cid/ciz021
[3] Thomas M. Hooton, Suzanne F. Bradley, Diana D. Cardenas, Richard Colgan, Suzanne E. Geerlings, James C. Rice, Sanjay Saint, Anthony J. Schaeffer, Paul A. Tambayh, Peter Tenke, Lindsay E. Nicolle, Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America, Clinical Infectious Diseases, Volume 50, Issue 5, 1 March 2010, Pages 625–663, https://doi.org/10.1086/650482
[4] Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA; American Society of Health-System Pharmacists; Infectious Disease Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013 Feb 1;70(3):195-283. doi: 10.2146/ajhp120568
[5] Moon E, Tam MD, Kikano RN, Karuppasamy K. Prophylactic antibiotic guidelines in modern interventional radiology practice. Semin Intervent Radiol. 2010 Dec;27(4):327-37. doi: 10.1055/s-0030-1267853
[6] Khurana N, Salei A, Gunn AJ, Huang J. Antibiotics Tubes and Lines. Semin Intervent Radiol. 2022 Nov 17;39(4):421-427. doi: 10.1055/s-0042-1758080
[7] Sutcliffe JA, Briggs JH, Little MW, McCarthy E, Wigham A, Bratby M, Tapping CR, Anthony S, Patel R, Phillips-Hughes J, Boardman P, Uberoi R. Antibiotics in interventional radiology. Clin Radiol. 2015 Mar;70(3):223-34. doi: 10.1016/j.crad.2014.09.021
[8] Beddy P, Ryan JM. Antibiotic prophylaxis in interventional radiology--anything new? Tech Vasc Interv Radiol. 2006 Jun;9(2):69-76. doi: 10.1053/j.tvir.2006.12.005

InpharmD's Answer GPT's Answer

Author:Muna Said, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Data on switches involving aflibercept biosimilars have evaluated single switches from reference aflibercept (Eylea) or other anti-vascular endothelial growth factor (VEGF) agents to an aflibercept biosimilar across multiple retinal conditions, predominantly neovascular age-related macular degeneration (nAMD, “wet” AMD) and diabetic macular edema (DME). Notably, no studies involving switches between aflibercept biosimilar products or repeated biosimilar switches were identified. Patients swit...

A 2026 narrative review examined the clinical evidence and switching strategies for anti-vascular endothelial growth factor (VEGF) biosimilars in ophthalmology for neovascular age-related macular degeneration (nAMD), including aflibercept, with particular consideration given to their implementation in France. The review identified the Phase 3 SB15 (aflibercept-yszy, Opuviz; Table 3) and ABP938 (aflibercept-ayyh, Pavblu; Table 1) trials as providing the strongest evidence for switching from reference aflibercept to a biosimilar, reporting no deterioration in visual acuity or anatomical outcomes and no increase in immunogenicity following a single switch. Additional real-world studies evaluated switching from aflibercept to the ranibizumab biosimilar Razumab in nAMD or diabetic macular edema (DME), with stable visual and anatomical outcomes through 12 months. However, the authors highlighted limitations including small sample sizes, short follow-up periods, limited large-scale Europea...

READ MORE→

A search of the published medical literature revealed 5 studies investigating the researchable question:

Provide a summary of aflibercept biosimilar switching studies, including any available from Europe.

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Mathis T, Uzzan J, Matonti F, et al. Anti-VEGF biosimilars in ophthalmology: from biosimilarity to clinical practice. JFO Open Ophthalmol. 2026;15:100205. doi:10.1016/j.jfop.2026.100205

InpharmD's Answer GPT's Answer

Author:Naveed Aijaz, PharmD, BCPS + InpharmD™ AI LEARN MORE 

A moderate body of literature supports intraoperative wound irrigation for surgical site infection (SSI) prevention in spinal surgery, although evidence comparing solutions and establishing optimal protocols remains limited. Expert consensus recommendations support considering aqueous povidone-iodine irrigation before wound closure in clean spinal procedures, while evidence remains insufficient to recommend for or against normal saline, chlorhexidine, or antibiotic-containing solutions for SS...

The 2024 European Association of Neurosurgical Societies (EANS) consensus recommendations on the diagnosis and management of de novo non-specific spinal infections were developed through a Delphi process involving 26 experts. Regarding surgical irrigation, the consensus recommends extensive irrigation of the entire surgical field with normal saline or an antiseptic solution during surgical management of spinal infections, with 93% expert agreement. However, the consensus does not specify a preferred antiseptic agent, irrigation concentration, volume, or frequency. Of note, the recommendations specifically address de novo non-specific spinal infections and do not include perioperative or postoperative spinal infections. [1] The 2020 Consensus on Wound Care of Surgical Site Infections (SSIs) in Spine Surgery was developed during the 2018 Second International Consensus Meeting on Musculoskeletal Infection, where 15 spine specialists reviewed available literature and discussed recomm...

READ MORE→

A search of the published medical literature revealed 8 studies investigating the researchable question:

What are the preferred irrigation solutions for spinal surgery? Do they differ for clean and contaminated procedures? Are there "best practices" available?

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Kramer A, Thavarajasingam SG, Neuhoff J, et al. Diagnosis and management of de novo non-specific spinal infections: European Association of Neurosurgical Societies (EANS) Spine Section Delphi consensus recommendations. Brain Spine. 2024;5:104178. Published 2024 Dec 31. doi:10.1016/j.bas.2024.104178
[2] Galetta MS, Kepler CK, Divi SN, et al. Consensus on Wound Care of SSI in Spine Surgery. Clin Spine Surg. 2020;33(5):E206-E212. doi:10.1097/BSD.0000000000000853
[3] Fuglestad MA, Tracey EL, Leinicke JA. Evidence-based Prevention of Surgical Site Infection. Surg Clin North Am. 2021;101(6):951-966. doi:10.1016/j.suc.2021.05.027
[4] Egu C, Muscogliati R, Nocun W, et al. RCT-based meta-analysis of povidone-iodine irrigation in spinal surgery: clarifying efficacy and safety. Eur Spine J. 2025;34(10):4670-4679. doi:10.1007/s00586-025-09243-8
[5] Mu X, Wei X, Li Z, Wei M, Wei J. Does intraoperative wound irrigation with diluted povidone-iodine prevent surgical site infection in spine surgery?. EFORT Open Rev. 2024;9(11):1087-1096. Published 2024 Nov 8. doi:10.1530/EOR-24-0091
[6] Torres KA, Konrade E, White J, et al. Irrigation techniques used in spine surgery for surgical site infection prophylaxis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2022;23(1):813. Published 2022 Aug 26. doi:10.1186/s12891-022-05763-2
[7] Shaffer A, Naik A, MacInnis B, et al. Perioperative prophylaxis for surgical site infections in pediatric spinal surgery: a systematic review and network meta-analysis. J Neurosurg Pediatr. 2022;31(1):43-51. Published 2022 Oct 28. doi:10.3171/2022.9.PEDS22316

InpharmD's Answer GPT's Answer

Author:Melissa Santibañez, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Current clinical guidelines recommend pretreatment dental evaluation for patients with cancer initiating antiresorptive therapy, including edentulous patients who wear dentures. The evaluation should include assessment of denture stability, fit, and areas of mucosal trauma, as denture use and ill-fitting dentures have been identified as risk factors for medication-related osteonecrosis of the jaw (MRONJ). Guidelines also recommend optimizing oral health before treatment when medically feasibl...

The 2019 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology/American Society of Clinical Oncology (MASCC/ISOO/ASCO) clinical practice guideline on medication-related osteonecrosis of the jaw (MRONJ) evaluated evidence from 132 publications to develop recommendations for the prevention and management of MRONJ in patients with cancer receiving bone-modifying agents (BMAs). For patients initiating BMAs in nonurgent settings, the guideline recommends a comprehensive dental, periodontal, and radiographic examination when feasible, followed by development of a dental care plan coordinated between the dentist and oncologist. Routine dental follow-up is recommended approximately every 6 months after treatment initiation. The guideline identifies denture use as a risk factor for MRONJ and specifically recommends addressing ill-fitting dentures as a modifiable risk factor. Preventive oral care and patient education are emphasized for both dentate and...

READ MORE→

A search of the published medical literature revealed 5 studies investigating the researchable question:

Should edentulous patients with dentures who are starting Zometa (intravenous zoledronic acid) for metastatic osseous disease obtain a dental clearance prior to treatment initiation?

Level of evidence
A - Multiple high-quality studies with consistent results  

READ MORE→

[1] Yarom N, Shapiro CL, Peterson DE, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol. 2019;37(25):2270-2290. doi:10.1200/JCO.19.01186
[2] Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022;80(5):920-943. doi:10.1016/j.joms.2022.02.008

InpharmD's Answer GPT's Answer

Author:Frances Beckett-Ansa, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Alternatives to oral iohexol (Omnipaque) for CT include other water-soluble iodinated agents, such as iopamidol and diatrizoate meglumine/diatrizoate sodium (Gastrografin), as well as barium sulfate and neutral oral contrast agents, depending on the clinical indication. In a randomized trial of 100 adults undergoing abdominopelvic CT, diatrizoate and iohexol provided similar gastrointestinal opacification, although iohexol was rated more favorably for taste; the study was not designed to esta...

According to the 2026 European Society of Urogenital Radiology (ESUR) Contrast Media Safety Committee guidelines, water-soluble iodinated contrast media are generally preferred for gastrointestinal opacification during computed tomography (CT). Oral agents include high-osmolality ionic contrast media, such as diatrizoate meglumine/sodium and ioxitalamate meglumine, and nonionic low- or iso-osmolality agents, including iohexol, iopamidol, ioversol, iopromide, iobitridol, and iodixanol. Dedicated, prediluted oral formulations of iohexol and iopamidol are available in selected markets. Nonionic low- and iso-osmolality agents are more palatable than high-osmolality ionic agents, and oral contrast use in abdominal CT has decreased. The most frequently reported adverse effects of oral iodinated contrast media are nausea, diarrhea, vomiting, and abdominal pain. Systemic absorption following gastrointestinal administration is approximately 1% to 2%, and hypersensitivity reactions are very r...

READ MORE→

A search of the published medical literature revealed 2 studies investigating the researchable question:

What alternatives can be used for oral contrast for CT since Omnipaque oral is not available. What is data on using Gastrograffin and how would it be dosed for this indication

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Sebastià C, van der Molen AJ, Vega F, et al. Safety of positive gastrointestinal contrast media. Updated guidelines by the ESUR Contrast Media Safety Committee. Eur Radiol. 2026;36(7):6007-6013. doi:10.1007/s00330-026-12399-6
[2] Patel A, Lalwani N, Kielar A. Use of oral contrast in 2024: primer for radiologists. Abdom Radiol (NY). 2024;49(8):2953-2959. doi:10.1007/s00261-024-04409-2
[3] Grist TM, Canon CL, Fishman EK, Kohi MP, Mossa-Basha M. Short-, mid-, and long-term strategies to manage the shortage of iohexol. Radiology. 2022;304(2):289-293. doi:10.1148/radiol.221183
[4] Pickhardt PJ. Positive Oral Contrast Material for Abdominal CT: Current Clinical Indications and Areas of Controversy. AJR Am J Roentgenol. 2020;215(1):69-78. doi:10.2214/AJR.19.21989

Why choose InpharmD™?

Find answers, not documents.

Before InpharmD™


BeforeTime
Your team spends hours per week cobbling together literature from different studies, many behind paywalls, leaving little time for action.
BeforeTime
TI opportunities are discovered (or presented by third parties) months after the fact, resulting in costly missed savings.
BeforeTime
Decisions may be made without a complete picture, or pushed out while gathering consensus.

After InpharmD™


BeforeTime
InpharmD™ delivers customized, actionable drug information in real time, so you can focus on execution.
BeforeTime
Your team stays informed immediately when new data emerges or prices change, and you’ll always be the first to know when any changes impact your formulary.
BeforeTime
With InpharmD™, your team can make faster, more informed decisions and move forward with confidence.

What Clinical Pharmacists Are Saying...


     

Assists in our research and is a great way or us to get an answer to a medical question without spending an average of 2 hours researching UptoDate or PubMed ourselves.


—   Jordan C., PharmD, New Jersey

     

Huge time saver with thorough responses.


—   Jane D., PharmD, Georgia

     

I’d never heard of a DI pharmacist before, now I have one. In. My. Pocket. Amazing!


     

Holy Shhh. Cow! Holy Cow! These summaries are beautiful.


—   Jane D., PharmD, Georgia

     

I just want to say: This is such a brilliant idea! You people are genius.


     

OH MY GOD WHERE HAVE YOU BEEN ALL MY LIFE!


     

I can’t tell you how much time I spend literature searching. And how I CANNOT STAND PAYWALLS. THIS IS UNBELIEVABLE!! (covers face for sec) thank you, thank you, thank you!


     

So they’re basically connecting academic researchers with front line providers and then automating everything. It’s simply brilliant.


     

The clinical pharmacist was our secret weapon anyway. (Smiles wryly) This pharmacist AI seems superhuman. I’m just blown away, honestly. (Looks at camera somberly.)


     

It’s an ENTIRE DI DEPARTMENT, that lives in Epic. Give me a second. I’m just having a hard time wrapping my head around that.


     

Sorry just give me a second, my mind is blown.


     

Stop reading and just download the app already! I’ve tried all of them. This is by far the most advanced, best-in-class.


What would you like to ask InpharmD™?

Sign up for a free trial & start right away.

Get Started Free